

Roberto Iacovelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3233480/roberto-iacovelli-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202
papers

3,552
citations

33
h-index

52
g-index

222
ext. papers

4,369
ext. citations

4.6
avg, IF

5
L-index

#	Paper	IF	Citations
202	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079580	5.4	0
201	Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?. <i>Anticancer Research</i> , 2022 , 42, 1487-1493	2.3	0
200	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations.. <i>Cancer Treatment Reviews</i> , 2022 , 105, 102379	14.4	1
199	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102377	14.4	2
198	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.. <i>Anticancer Research</i> , 2022 , 42, 165-172	2.3	0
197	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 727	3.6	0
196	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
195	Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study. <i>Biology</i> , 2021 , 10,	4.9	1
194	Methylation study of the Paris system for reporting urinary (TPS) categories. <i>Journal of Clinical Pathology</i> , 2021 , 74, 102-105	3.9	4
193	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021 , 4, 274-281	6.7	5
192	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211022870	3.2	1
191	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1029-1054	3.5	4
190	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021 , 16, 625-632	5	2
189	2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1203-1206	3.5	
188	Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1207-1210	3.5	0
187	Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer. <i>Annals of Oncology</i> , 2021 , 32, 1192-1193	10.3	
186	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021 , 80, 497-506 ^{10.2}		3

185	Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102295	14.4	4
184	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11
183	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	1
182	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 477-488	3.3	8
181	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 195-205	3.8	4
180	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to PatientsPAge: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020 , 43, 95-103	5	3
179	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5559-5559	2.2	1
178	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 16-16	2.2	3
177	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS762-TPS762	2.2	
176	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS596-TPS596	2.2	
175	Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 123-123	2.2	
174	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5569-5569	2.2	0
173	Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. <i>Cancer Treatment and Research Communications</i> , 2020 , 22, 100161	2	9
172	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 199-206	6.2	5
171	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020 , 15, 495-501	5	12
170	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 654-660	6.2	1
169	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 798.e17-798.e24	2.8	4
168	Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020 , 136, 195-203	7.5	24

167	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020 , 11, 4333	17.4	31
166	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1513-1525	21.7	13
165	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019 , 11,	6.6	18
164	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019 , 17, 296	8.5	7
163	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2506-2518	59.2	219
162	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , 2019 , 46, 65-72	5.5	10
161	Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma. <i>Lancet Oncology, The</i> , 2019 , 20, e124	21.7	1
160	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 83-86	7	5
159	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 529.e1-529.e7	2.8	4
158	Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1283-1289	3.8	12
157	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 141-152	7	11
156	CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2019 , 30, v882-v883	10.3	2
155	Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. <i>Current Urology</i> , 2019 , 12, 216-222	1.7	
154	Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC). <i>Annals of Oncology</i> , 2019 , 30, v372-v373	10.3	2
153	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 148-148	2.2	6
152	Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 615-615	2.2	3
151	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5050-5050	2.2	
150	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14

149	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 921-930	3.8	5
148	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , 2019 , 42, 269-273	5	10
147	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 917-927	2.5	2
146	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019 , 11,	6.6	1
145	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 42-45	2.7	12
144	Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e150-e155	3.3	7
143	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e187-e194	3.3	9
142	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018 , 10, 65-77	3.2	14
141	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e645-e653	3.3	68
140	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 161-175	3.5	12
139	Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018 , 67, 29-33	14.4	3
138	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018 , 24, 447-456	2.6	12
137	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. <i>Anticancer Research</i> , 2018 , 38, 4913-4918	2.3	3
136	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 937-945	5.4	10
135	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. <i>Urologia Internationalis</i> , 2018 , 101, 38-46	1.9	23
134	Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1069-e1071	3.3	12
133	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
132	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018 , 70, 67-74	14.4	26

131	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018 , 70, 112-117	14.4	11
130	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018 , 14, 2559-2564	3.6	5
129	De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 482-484	3.3	4
128	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 705-709	2.4	1
127	NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4602-TPS4602	2.2	3
126	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. <i>Anticancer Research</i> , 2018 , 38, 3105-3110	2.3	3
125	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <i>Cancers</i> , 2018 , 11,	6.6	5
124	Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. <i>Annals of Oncology</i> , 2018 , 29, viii316	10.3	2
123	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 526.e13-526.e18	2.8	4
122	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <i>Pathology Research and Practice</i> , 2018 , 214, 1675-1680	3.4	1
121	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018 , 13, 649-655	5	13
120	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 355-359.e1	3.3	22
119	Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>Eur Urol</i> 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future. <i>European Urology</i> ,	10.2	
118	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017 , 54, 68-73	14.4	52
117	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 541.e7-541.e13	3.8	9
116	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , 2017 , 9, 579-587	3.8	10
115	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017 , 60, 152-157	14.4	25
114	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017 , 8, 7328-7335	3.3	16

113	Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutic target for patients at risk for bone metastases. <i>International Journal of Biological Markers</i> , 2017 , 32, e243-e247	2.8	7
112	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. <i>Journal of Onco-Nephrology</i> , 2017 , 1, 132-142	0.2	2
111	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. <i>European Journal of Cancer</i> , 2017 , 83, 237-246	7.5	20
110	Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. <i>Anti-Cancer Drugs</i> , 2017 , 28, 206-212	2.4	7
109	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e191-e198	3.8	9
108	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5030-5030	2.2	3
107	Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 435-435	2.2	2
106	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017 , 18, 692-699	3.5	7
105	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e585-e585	2.2	
104	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 254-254	2.2	
103	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 230-230	2.2	
102	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16521-e16521	2.2	
101	The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16063-e16063	2.2	
100	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 24-8	7	16
99	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2016 , 11, 569-577	5	12
98	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. <i>Future Oncology</i> , 2016 , 12, 2001-8	3.6	5
97	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016 , 11, 143-8	5	108
96	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 324-31	7	11

95	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016 , 45, 46-57	14.4	117
94	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016 , 11, 337-43	5	18
93	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. <i>Oncology Reviews</i> , 2016 , 10, 293	4.3	38
92	The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016 , 49, 37-44	14.4	42
91	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015 , 137, 1467-74	7.5	25
90	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015 , 51, 473-481	7.5	12
89	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
88	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015 , 26, 2107-13	10.3	66
87	Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. <i>Oncology</i> , 2015 , 88, 133-8	3.6	4
86	The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1970-7	7.5	27
85	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 581-8	3.8	41
84	Sunitinib 2 weeks on, 1 off: strengths and weaknesses. <i>Annals of Oncology</i> , 2015 , 26, 1511-2	10.3	2
83	Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 286-94	3.2	2
82	Everolimus and tamsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 137-41	3.3	16
81	Emerging tyrosine kinase inhibitors for the treatment of renal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 379-92	3.7	2
80	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 765-73	9.6	28
79	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015 , 68, 154-60	10.2	37
78	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43

77	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015 , 136, 1-10	7.5	41
76	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015 , 10, 127-33	4	1
75	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015 , 9, 263-7	1.2	6
74	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 156-66	7	50
73	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 59-68	3.2	2
72	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 587-94	7.5	329
71	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
70	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , 2015 , 10, e0120427	3.7	8
69	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 32161-8	3.3	24
68	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , 2015 , 16, 164-70	3	36
67	Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. <i>Canadian Urological Association Journal</i> , 2015 , 9, E172-7	1.2	30
66	Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. <i>European Urology</i> , 2014 , 65, 713-20	10.2	54
65	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014 , 135, 763-73	7.5	33
64	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 271-5	14.4	71
63	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 929-38	3.8	50
62	Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?. <i>Cancer Biology and Therapy</i> , 2014 , 15, 486-8	4.6	2
61	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , 2014 , 9, e92147	3.7	17
60	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , 2014 , 8, E121-5	1.2	7

59	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 107-16	2.1	5
58	Clinical and pathological features of primary renal angiosarcoma. <i>Canadian Urological Association Journal</i> , 2014 , 8, E223-6	1.2	8
57	Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. <i>British Journal of Cancer</i> , 2014 , 110, 1778-84	8.7	40
56	First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. <i>Cancer Biology and Therapy</i> , 2014 , 15, 19-21	4.6	5
55	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , 2014 , 19, 845-50	5.7	37
54	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014 , 10, 1741-50	3.6	11
53	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology, The</i> , 2014 , 15, e581	21.7	1
52	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 1228-37	3.8	32
51	Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 611-5	2.7	10
50	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014 , 10, 1361-72	3.6	6
49	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. <i>PLoS ONE</i> , 2014 , 9, e108940	3.7	46
48	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 321-31	9.6	21
47	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 471-477	2.2	7
46	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014 , 2, 835-9	1.6	21
45	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014 , 100, e282-e285	1.7	
44	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 448-448	2.2	
43	Treatment of collecting duct carcinoma: current status and future perspectives. <i>Anticancer Research</i> , 2014 , 34, 1027-30	2.3	17
42	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 397-401	4.8	16

41	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013 , 109, 1755-9	8.7	70
40	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
39	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 323-7	6.2	9
38	Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney. <i>Urology</i> , 2013 , 82, 382-6	1.6	51
37	Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules. <i>Oncology</i> , 2013 , 84, 92-9	3.6	7
36	Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher". <i>Acta Oncologica</i> , 2013 , 52, 1235	3.2	
35	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>Cancer</i> , 2013 , 119, 3377-84	6.4	144
34	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 431-431 ²		1
33	Clinical outcome (CO) and predictive factors (PRE) evaluation of young (<60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16031-e16031	2.2	
32	Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2013 , 33, 5663-6	2.3	6
31	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8	5.6	37
30	Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature. <i>BJU International</i> , 2012 , 110, 1449-54	5.6	35
29	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. <i>BJU International</i> , 2012 , 110, 1747-53	5.6	47
28	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012 , 16, 464-7	2.5	25
27	Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib. <i>International Journal of Dermatology</i> , 2012 , 51, 221-2	1.7	10
26	Gemcitabine-induced extensive skin necrosis. <i>Case Reports in Medicine</i> , 2012 , 2012, 831616	0.7	4
25	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1001-8	4.6	5
24	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012 , 107, 1227-32	8.7	18

23	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. <i>Acta Oncologica</i> , 2012 , 51, 873-9	3.2	51
22	Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 107-11	3.2	2
21	Abiraterone acetate in castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2012 , 23, 247-54	2.4	4
20	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 397-397	2.2	9
19	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4621-4621	2.2	
18	Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4629-4629	2.2	
17	Umbilical Node as First Clinical Appearance in a Patient with a High Tumor Burden. <i>American Surgeon</i> , 2011 , 77, 248-249	0.8	
16	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1631-40	3.5	16
15	Umbilical node as first clinical appearance in a patient with a high tumor burden. <i>American Surgeon</i> , 2011 , 77, E248-9	0.8	
14	Circulating tumor cells and "suspicious objects" evaluated through CellSearch [®] in metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2011 , 31, 4219-21	2.3	47
13	Renal Cell Carcinoma: Incidence and Cost Estimation in the Era of Targeted Therapy. <i>Tumori</i> , 2010 , 96, 361-361	1.7	1
12	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. <i>Tumori</i> , 2010 , 96, 794-795	1.7	1
11	Neoadjuvant targeted therapy in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010 , 7, doi:10.1038/nrurol.2010.2-c1; author reply doi:10.	5.5	1
10	Past, present and future of targeted therapy in solid tumors. <i>Current Cancer Drug Targets</i> , 2010 , 10, 433-68	6.8	26
9	The end of chemotherapy in renal cell carcinoma: for much but not for all. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 522-3	2.7	
8	Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 2073-7	5.6	56
7	Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma. <i>Acta Biomedica</i> , 2010 , 81, 68-71	3.2	3
6	Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?. <i>Open Medicine (Poland)</i> , 2009 , 4, 138-139	2.2	

- 5 Neo-adjuvant and adjuvant chemotherapy in bladder cancer. *Annals of Oncology*, **2007**, 18 Suppl 6, vi162-3. 2
- 4 Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum. *Anticancer Research*, **2007**, 27, 2743-6 2,3 20
- 3 Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up. *Anticancer Research*, **2007**, 27, 4491-4 2,3 9
- 2 Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. analysis of risk factors. *Anticancer Research*, **2006**, 26, 3167-70 2,3 6
- 1 Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. A multicenter study. *Anticancer Research*, **2006**, 26, 3171-4 2,3 6